ADR-001

N/A

Report date: 2023/01/12 15:31:41

Base Information

Drug NameADR-001
Drug Alias NameADR-001
ClassificationCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapyCell and gene therapy > Cell therapy > Source of cells > Adipose-derived
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsCoronavirus Disease 2019 (COVID-19)Glomerulonephritis, IGALiver Cirrhosis
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryJapan
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaN/A
Originator CompaniesRohtoNiigata UniversityShionogi & Co Ltd
China Registration ClassN/A

Develop Information

Active CompaniesRohto Pharmaceutical Co LtdNagoya UniversityShionogi & Co Ltd
Inactive CompaniesN/A
Active IndicationsCoronavirus Disease 2019 (COVID-19)Glomerulonephritis, IGALiver Cirrhosis
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A